Skip to main content

Unable to load price data. Sorry.



CAPS Rating: No stars

A pharmaceutical company focused on developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:POZN.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

line70day (< 20)
Submitted December 11, 2013

Aquired US rights to arthritis treatment Vimovo from Asta Zeneca Surged 32% it will recieve a 10% royalty from Horizon as part of the deal. Horizan with a full-year rev. in the range of $190 M - $205 M

pbtoau78 (87.00)
Submitted May 12, 2010

This is a classic example of a false moat. Building off zzlangerhans' example of treximet, Vimovo which is falsely being labeled as a "pain drug" (NSAIDs are fundamentally anti-inflammatory drugs- which secondarily may reduce pain levels) is a… More


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about POZN.DL.

No one has written a Pitch for POZN.DL stock yet. Tell us why you think POZN.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in POZN.DL.

No players have picked POZN.DL yet. Tell us why you think POZN.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for POZN.DL.